Background: Common dermatological disorders induced by the human papillomavirus (HPV) include warts (both cutaneous and genital). It's not dangerous, but it's unpleasant to look at, can spread to others, and sometimes koebnerizes. So, it's crucial to get the right care at the right time. Several conventional therapies are available, although their efficacy varies. Noninvasive, user-friendly, and showing great promise, topical and systemic immunotherapy has quickly become a mainstay in the treatment of warts. Objective: Assessment of Growing role of immunotherapy in treatment of warts. Methods: We searched PubMed, Google Scholar, and Science Direct for information on Immunotherapy with Warts and human papillomavirus. However, only the most current or comprehensive study from April 2005 to July 2022 was considered. The authors also assessed references from pertinent literature. Documents in languages other than English have been disregarded since there aren't enough resources for translation. Unpublished manuscripts, oral presentations, conference abstracts, and dissertations were examples of papers that weren't considered to be serious scientific research. Conclusion: Intralesional immunotherapy using Candida antigen has the benefits of being inexpensive, showing promise, being simple and easy to inject into a single wart. A promising immunotherapeutic strategy is intralesional injection of the Candida antigen. In both injected and non-injected lesions, this modality is related to Th1 cytokines production.